STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNTI
  4. [8-K] Senti Biosciences, Inc. Reports Material Event

[8-K] Senti Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SNTI logo
Senti Bioscience

NASDAQ:SNTI

SNTI Rankings

#8996 Ranked by Market Cap
N/A Ranked by Dividends

SNTI Latest News

Jul 18, 2025
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
Jun 30, 2025
Senti Bio Participates in Nasdaq Amplify Spotlight Series
Jun 24, 2025
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
Jun 18, 2025
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Jun 9, 2025
Senti Biosciences Announces New Employment Inducement Grants

SNTI Latest SEC Filings

Jun 30, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event
Jun 27, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jun 27, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jun 27, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jun 27, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity

SNTI Stock Data

60.51M
11.16M
279.35%
178.76%
1.46%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO